{"id":"W4205351508","doi":"10.1016/j.jval.2021.04.274","title":"PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canada","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Oncology; Internal medicine; Chemotherapy; Progression-free survival; Quality of life (healthcare); Lung cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002794093,0.001054208,0.001961477,0.0009357615,0.0005977546,0.001553022,0.001396419,0.0008603898,0.003690608],"category_scores_gemma":[0.007744448,0.0004994386,0.003767391,0.001537612,0.0006996071,0.0006081078,0.0007350977,0.001620483,0.0001361776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05174311,"about_ca_system_score_gemma":0.03609177,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.835692,"about_ca_topic_score_gemma":0.8138629,"domain_scores_codex":[0.9976122,0.001167184,0.0001241592,0.0001951196,0.000406039,0.0004953242],"domain_scores_gemma":[0.9972728,0.001114536,0.0003310771,0.00006318048,0.0005091023,0.0007092785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.3689846,0.006365709,0.08022789,0.007253085,0.02317882,0.0008316059,0.0003593684,0.3140028,0.002676562,0.005803281,0.01186219,0.1784541],"study_design_scores_gemma":[0.1020688,0.0499873,0.3328716,0.002428723,0.04395373,0.0008775128,0.001546141,0.4481233,0.002169306,0.003202526,0.01232226,0.000448702],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770654,0.01121112,0.0007319315,0.001309095,0.0001408153,0.0009089262,0.004157847,0.00003706025,0.004437806],"genre_scores_gemma":[0.9961582,0.001245591,0.0005458173,0.0001414688,0.00002322931,0.00009628163,0.001130831,0.000005852121,0.0006528227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.164308,"threshold_uncertainty_score":0.3754243,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2546435512431814,"score_gpt":0.4184204429304267,"score_spread":0.1637768916872453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}